Combination of diethylpropion with dietary intervention results in body weight and fat loss with preserved muscle mass in obese patients.

Autor:	Nugraha GI; Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.; Cardiometabolic Working Group Study, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia., Amalia F; Cardiometabolic Working Group Study, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia., Imadudda'wah F; Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia., Ariyanto EF; Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.; Cardiometabolic Working Group Study, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia., Ghozali M; Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.; Cardiometabolic Working Group Study, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia., Fatimah SN; Cardiometabolic Working Group Study, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.; Department of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2024 Sep 27; Vol. 103 (39), pp. e39908.
DOI:	10.1097/MD.0000000000039908
Abstrakt:	Combining pharmacotherapy with lifestyle intervention is recommended for obese class II patients who fail lifestyle therapy and for obese class I patients. Diethylpropion, an obesity medication, has been approved for use in Indonesia, which is an Asia-Pacific country. This retrospective study aimed to assess the short-term effects of diethylpropion on weight and fat loss in obese patients in Indonesia. Secondary data were collected from 142 patients' medical records with a body mass index ≥ 25 kg/m2 who underwent short-term diethylpropion treatment for 84 days between January 2022 and November 2023 at the Kimia Farma Nutrition Clinic in Bandung, Indonesia. Blood pressure, body weight, height, waist circumference, and body composition were assessed at each follow-up visit to determine the fat and muscle mass. Patients were prescribed diethylpropion 25 mg 3 times daily every 2 weeks together with dietary intervention. Kruskal-Wallis test was used to analyze the changes in body weight, skeletal muscle, fat mass, and waist circumference after the diethylpropion therapy. Mann-Whitney test was used for the relation between age, sex, and body mass index with weight loss on the last day of follow-up. Simple linear regression analysis was also performed to identify the correlation between weight loss and therapy duration. This study showed body weight reduction of up to 9.5 ± 3 kg (10 ± 0.0%) (P = .008) on 84 days of treatment. Significant fat loss 11.5 ± 4.6 kg (20.5 ± 0.0%) (P = .005) was also reported in our study without significant loss of muscle mass -2.4 ± 4.6 kg (3.6 ± 1.3%) (P = .58). Waist circumference was insignificantly reduced by 5.6 ± 0.0 cm (4.9 ± 2.8%) (P = .21) after 84 days of diethylpropion therapy. This study revealed no significant changes in patient systolic and diastolic pressures despite showing mild increases after 70 days. The combination of diethylpropion and an appropriate diet resulted in weight loss accompanied by significant fat loss and preserved muscle mass without an increase in blood pressure during the 12-week treatment period. Competing Interests: The authors have no funding and conflicts of interest to disclose. (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu